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Summary Cellular oncogenes have been identified by the biological activity of tumour DNAs in transfection
assays and/or by homology to the transforming genes of retroviruses. In some tumours, the biological
activity, organization or expression of these genes is altered, suggesting that such alterations contribute to the
development of neoplastic disease. Experiments leading to the identification of cellular oncogenes are reviewed
and our current understanding of the mechanisms by which they induce transformation of cells in culture and
may contribute to the pathogenesis of neoplasms in vivo is discussed.
Detection of cellular transforming genes by
transfection
The biological activity of tumour DNAs, detected
by transfection of NIH 3T3 mouse cells, has led to
the identification of transforming genes which are
activated in a variety of human and animal
neoplasms. The basic observation is that DNAs of
many tumours induce transformation of NIH 3T3
cells with high efficiencies. In contrast, DNAs of
normal cells lack efficient transforming activity,
including normal DNAs of the same individual
animals or patients whose tumour DNAs induce
transformation. These findings imply that the
development of many neoplasms involves dominant
genetic alterations leading to the activation of
transforming genes which are then detectable by
their biological activity in this gene transfer assay.
The transfection assay for cellular transforming
genes is based on work of Hill & Hillova (1972),
who demonstrated transfer of biologically active
proviral DNA from cells infected with Rous
sarcoma virus. Improvements in the transfection
technique, including the use of NIH 3T3 cells as
recipients which efficiently integrate exogenous
DNA, have allowed extension of this approach to
cellular, in addition to viral, transforming genes.
The initial observations of transforming genes of
cellular origin demonstrated transformation of NIH
3T3 cells by DNAs of some chemically-transformed
mouse cell lines (Shih et al., 1979) and by DNA
fragments of normal cells (Cooper et al., 1980).
High molecular weight DNAs ofnormal cells lacked
transforming activity (Shih et al., 1979; Cooper
et al., 1980), whereas DNAs of some chemically-
transformed cells induced transformation with 0.1-1
transformants jg- 1 DNA (Shih et al., 1979). In
addition, DNA fragments (0.5-5 kb) of normal
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chicken and mouse cells induced transformation
with low efEfciency (0.003 transformants ig-1
DNA) (Cooper et al., 1980). DNAs of NIH cells
transformed by these normal cell DNAs induced
transformation with high efficiencies in secondary
transfection assays (0.1-1 transformants ug-1
DNA), indicating that these transformed cells
contained activated transforming genes, presumably
generated by DNA rearrangements during the
primary DNA integration process (Cooper et al.,
1980). These experiments have recently been
confirmed and extended to fragments of normal
human DNA (Schafer et al., 1984). In addition to
demonstrating the utility of the transfection assay
for detection of cellular transforming genes, these
experiments indicated that (i) normal cells
contained genes which were potentially capable of
inducing transformation and (ii) some chemically-
transformed cells contained activated genes which
induced transformation with high efficiencies.
Application of this approach to naturally
occuring tumours initially led to the identification
of activated transforming genes in chicken B cell
lymphomas (Cooper & Neiman, 1980), a human
bladder carcinoma cell line (Krontiris & Cooper,
1981; Shih et al., 1981) and carcinogen-induced
rodent carcinomas and neuroblastomas (Shih et al.,
1981). Subsequently, activated transforming genes
have been detected in many different types of
neoplasms (carcinomas, sarcomas, neuroblastomas,
melanomas, lymphomas and leukaemias) of human,
rodent and avian origin. Some of the transforming
genes identified by this approach are related to the
ras genes of Harvey and Kirsten sarcoma viruses,
whereas others are unrelated to previously
described retroviral transforming genes.
Distribution of activated genes in neoplasms
Three different members of the ras gene family
have been identified as biologically active
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transforming genes in neoplasm DNAs: rasH, ras
and rasN (Der et al., 1982; Parada et al., 1982;
Santos et al., 1982; Hall et al., 1983; Shimizu et al.,
1983b) (Table I). These genes have been detected in
many different types of neoplasms including
carcinomas, sarcomas, melanomas, neuroblastomas,
lymphomas and leukaemias of myeloid and
lymphoid origin. Thus it appears that ras genes can
contribute to the development of neoplasms arising
from multiple types of differentiated cells. This is
consistent with the fact that ras genes are expressed
in all normal vertebrate cells which have been
examined. In addition, yeast contain functional ras
genes, suggesting that these genes play a
fundamental role in cell proliferation which is
highly conserved in evolution. However, ras genes
are found as active transforming genes in only a
small fraction (-.10-20%) of individual neoplasms.
Thus, although ras activation can occur in many
different types of tumours, it is apparently not a
necessary event for development of any particular
type of neoplasm. In addition, recent data suggests
that ras activation may be a late event in tumour
progression. For example, Albino et al. (1984) have
reported detection of an activated rasN gene in only
one out of five metastases of an individual
melanoma patient. This finding suggests the
possibility that ras activation may, when it occurs,
impart a selective advantage to a clone of
neoplastic cells, but is not essential for formation of
a primary neoplasm or even its metastatic
derivatives.
In contrast to ras genes, some of the other
transforming genes detected by transfection are ac-
tivated highly reproducibly in neoplasms of specific
cell types. For example, Blym-1 (Table I) has been
detected as an activated transforming gene in all
surface immunoglobulin-positive B cell lymphomas
of either chicken, mouse or human origin which
have been examined (Cooper & Neiman, 1980;
Lane et al., 1982b; Diamond et al., 1983). However
distinct transforming genes are activated in T cell
neoplasms (Tlym-I and tx-3) and in B cell neoplasms
representing other stages of B lymphocyte differen-
tiation (tx-I in pre B cell neoplasms and tx-2 in
myelomas and plasmacytomas) (Table I) (Lane et
al., 1982b, 1984). The activation of these
transforming genes appears specific to neoplasms
representing discrete stages of B and T lymphocyte
differentiation and occurs in the majority (80-100%)
of individual neoplasms of the appropriate cell
type (Lane et al., 1982b). The spectrum of
activation of these genes in neoplasms thus suggests
that they play a more reproducible role in the
development of specific types of tumours than the
ras genes.
Ras gene activation and function
The ras genes all encode proteins of approxi-
mately 21,000 daltons which are designated p21s.
Experimental manipulations of the normal human
rasH gene have shown that over-expression of the
normal gene product is sufficient to induce cell trans-
formation (Chang et al., 1982). However, activation
of ras genes in human tumours is commonly a
consequence of structural, rather than regulatory,
mutations (Tabin et al., 1982; Reddy et al., 1982;
Taparowsky et al., 1982, 1983; Der & Cooper,
Table I Neoplasm transforming genes detected by transfection
Human
rasH bladder and lung carcinoma
rasK lung, colon, bladder, pancreatic,




promyelocytic leukaemia, acute, myelogenous
leukaemia, Burkitt's lymphoma, T cell ALL,
colon carcinoma, melanoma, teratocarcinoma
Blym-i Burkitt's lymphomas
Tlym-I T cell lymphomas
tx- pre B cell neoplasms
tx-2 myelomas





epithelial and mammary carcinomas




pre B cell neoplasms
plasmacytomas
mature T cell neoplasms
mammary carcinomas
promoter-responsive epidermal cells
'C. Cooper et al. (1984).
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1983; Capon et al., 1983a, b; Shimizu et al., 1983a,
1983a; Yuasa et al., 1983). The mutations in
tumours which have been analyzed to date alter
either codon 12 or codon 61. At either of these
positions, substitution of multiple different amino
acids is sufficient to endow p21 with transforming
activity. In addition, most activating mutations
appear to induce conformational alterations in p21
which are detectable by abnormal electrophoretic
mobilities (Tabin et al., 1982; Der & Cooper, 1983;
Yuasa et al., 1983). Taken together, these
observations suggest that substitution of a variety
of abnormal amino acids at these critical loci may
inactivate a regulatory domain of p.21, thus
resulting in abnormal p21 function in vivo.
Studies of viral ras proteins have indicated that
they are localized to the inner face of the plasma
membrane (Willingham et al., 1980; Furth et al.,
1982) and modified by acylation (Sefton et al.,
1982). The only established biochemical activity
common to all viral ras transforming proteins
binding is guanine nucleotide binding (Scolnick et
al., 1979, Furth et al., 1982).
To attempt to elucidate the biochemical basis for
the transforming activity of mutant p2ls in human
tumours, we have compared the biochemical
properties of p21s encoded by normal and activated
human ras genes. These experiments indicated that
both normal and transforming human p21s were
localized to the plasma membrane and were
modified to similar extents by post-translational
acylation (Finkel et al., 1984). Neither normal nor
activated p2ls were glycosylated or phosphorylated
(Der & Cooper, 1983; Finkel et al., 1984). Thus the
subcellular localization and post-translational
processing of human p2ls were not altered by ras
gene activation.
Since guanine nucleotide binding represented the
only biochemical activity of p21, we investigated
the possibility that the affinity or specificity of p21
for nucleotides was altered as a consequence of
mutational activation. However, the GTP binding
affinities of both normal and activated human p2ls
were indistinguishable (KD'S of 1-2 x 10-8 M) and
both the normal and activated proteins were
specific for GTP and GDP binding (Finkel et al.,
1984). Thus mutational activation of p21 does not
directly affect its intrinsic nucleotide binding
properties.
In order to investigate the physiologic function of
ras proteins, we have attempted to identify other
cellular proteins with which p21 might interact
(Finkel & Cooper, 1984.) Immunoprecipitation of
extracts of human carcinoma cell lines with anti-
p21 monoclonal antibodies revealed the co-
precipitation of a second protein of 90,000
daltons. This coprecipitated protein was identified
as the transferrin receptor by three criteria: (i)
comigration in both reducing and non-reducing
gels, (ii) immunological reactivity with monoclonal
antibody raised against transferrin receptor, and
(iii) identity of partial proteolysis maps of the
90,000 dalton coprecipitated protein and transferrin
receptor. Coprecipitation of transferrin receptor
was detected with three different ras monoclonal
antibodies and was dependent on the presence of
ras proteins in cell extracts, indicating that p21 and
transferrin receptor form a molecular complex. This
complex was dissociated by addition of transferrin
to cell extracts, suggesting that transferrin binding
induced a conformational change in the receptor
which led to the dissociation of ras proteins.
Transferrin is an iron-binding protein which is
required for the growth of most cells in culture.
Expression of transferrin receptor is closely
correlated with cell proliferation. Furthermore,
monoclonal antibodies against transferrin receptor
inhibit cell growth, in some cases even if iron is
supplied in an alternate form. Transferrin and its
receptor thus appear to play a fundamental role in
the growth of many differentiated cell types. The
findings of interaction between ras proteins and
transferrin receptor therefore suggest that p21 may
function in conjunction with this cell surface
receptor in regulation of cell growth, perhaps by
transducing growth signals mediated by transferrin
binding. It is possible that the role of p21 in this
respect is analogous to other membrane guanine
nucleotide binding proteins, such as the adenyl
cyclase G proteins and transducin (Gilman, 1984).
Blym transforming genes
The Blym-1 transforming' gene was initially
identified in DNAs of chicken B cell lymphomas
(Cooper & Neiman, 1980) and was isolated as a
molecular clone by sib-selection (Goubin et al.,
1983). The cloned chicken Blym-J gene was
unusually small (only 600 nucleotides) and its
nucleotide sequence indicated that it encoded a
small protein of 65 amino acids (Goubin et al.,
1983). Comparison of the predicted chicken Blym-J
amino acid sequence with sequences of known
cellular proteins revealed partial homology (36%)
between the chicken Blym-1 protein and the
aminoterminal region of transferrin family proteins
(Goubin et al., 1983). This homology was
concentrated in regions which were conserved
between different members of the transferrin family,
suggesting a common ancestry for chicken Blym-J
and a region of the transferrins, as well as
stimulating the speculation that this homology
might also suggest a functional relationship.
Blot hybridization analysis indicated that the
chicken Blym-J gene was a member of a small140 G.M. COOPER
family of related genes which were present in
human as well as chicken DNA. We therefore
investigated the possibility that the transforming
gene detected by transfection of Burkitt's
lymphoma DNAs might be a member of the human
gene family defined by homology to chicken Blym-
1. A genomic library of DNA from a Burkitt's
lymphoma was screened using chicken Blym-1
probe and a biologically active human transforming
gene, designated human Blym-], was isolated
(Diamond et al., 1983). This human homologue of
chicken Blym-1 was found to represent the
transforming gene detected by transfection of six
out of six Burkitt's lymphoma DNAs studied.
Restriction mapping and nucleotide sequencing
indicate that human Blym-1, like chicken Blym-J, is
quite small ('- 700 nucleotides) Diamond et al.,
1983 and manuscript submitted). Also like chicken
Blym-1, the sequence of human Blym-J predicts a
small protein (58 amino acids) which consists of two
exons and is rich in lysine and arginine. Alignment
of the human and chicken Blym-J amino acid
sequences indicates 33% amino acid identities. The
human and chicken Blym-J proteins are therefore
clearly related (P<0.005), but significant divergence
between the two sequences has occurred. This
divergence suggests the possibility that the chicken
and human genes may represent relatively distant
members of the Blym family.
In spite of the divergence between the chicken
and human Blym-J genes, the human Blym-J
sequence also displays significant homology (20%)
to the amino-terminal region of transferrins.
Significantly, amino acids which are conserved
between the chicken and human Blym-J genes also
tend to be conserved between different members of
the transferrin family. It is unlikely that such
divergent sequences as chicken and human Blym-J
have maintained homology to transferrin by
chance. Rather, the conservation of transferrin
homology in these Blym transforming genes
suggests that this homology reflects some functional
property of the Blym transforming proteins. In view
of the molecular interaction between ras proteins
and transferrin receptor, these findings suggest the
hypothesis that the Blym transforming genes may
also affect cell proliferation via a pathway related
to transferrin and its surface receptor.
Oncogene activation and pathogenesis of neoplasms
The development of neoplasms in vivo clearly
involves progressive pre-neoplastic and neoplastic
stages rather than occurring as a single-step
conversion of a normal cell to a fully neoplastic
cell. Therefore we have regarded the transforming
genes detected by transfection of tumour DNAs as
representing only one event in neoplasm
development. In fact, many neoplasms involve
activation of at least two distinct oncogenes,
suggesting that different oncogenes may function at
different stages of neoplasm development.
In chicken B cell lymphomas, the Blym-1 gene is
detected by the transfection assay (Cooper &
Neiman, 1980). However, a different gene (myc) is
activated in the same tumours by adjacent
integration of viral DNA (Hayward et al., 1981).
Blym-J and myc are unrelated to each other and
are not closely linked in cellular DNA (Cooper &
Neiman, 1981). Thus, their co-activation in these
neoplasms represents two distinct events. Since both
genes are reproducibly activated in the vast
majority (90%) of individual lymphomas, both
appear to play important roles in the disease
process.
Human myc and Blym-1 genes are also both
activated in Burkitt's lymphomas. In this disease,
human myc is translocated from chromosome 8 to
an immunoglobulin locus (Dalla-Favera et al.,
1982; Taub et al., 1982). In the same tumours,
human Blym-J, which is located on chromosome 1
(Morton et al., 1984), is detected as an active
transforming gene in the transfection assay
(Diamond et al., 1983). Thus the same two
oncogenes are involved in B cell lymphomas of
both chicken and man. The reproducible activation
of both myc and Blym in this disease in two
different species presents a strong argument for the
causal role of both genes in the disease process.
The initial stage in the pathogenesis of B cell
lymphomas in the chicken is the outgrowth of pre-
neoplastic transformed lymphoid follicles (Neiman
et al., 1980). Approximately 10-100 such hyper-
proliferative lesions are observed out of ^ 105
lymphocyte follicles in the bursa. These pre-
neoplastic follicles retain the organization of
normal lymphoid follicles and the majority appear
to regress under the normal physiological controls
which mediate regression in the bursa. However, a
small fraction (<5%) of these pre-neoplastic
follicles are instead thought to progress to clonal
neoplasms (Neiman et al., 1980).
Activation of both myc and Blym-J has occurred
in the earliest detectable clonal bursal neoplasms
(Cooper & Neiman, 1981). Since the disease process
is initiated by infection with a virus which activates
myc, it is attractive to speculate that activation of
myc is directly responsible for pre-neoplastic follicle
proliferation but is insufficient to induce the full
neoplastic phenotype. Activation of Blym within
some pre-neoplastic lymphocytes would then
represent a second event responsible for progression
to neoplasia.
Recent evidence in support of this hypothesis hasACTIVATION OF TRANSFORMING GENES IN NEOPLASMS 141
come from experiments in which the biological
effects of an activated myc gene on bursal
lymphocytes have been investigated (Neiman et al.,
manuscript submitted). Activated myc was
introduced into bursal lymphocytes by infection
with the retrovirus HB1, which contains a myc gene
recovered by recombination from chicken DNA
(Bister et al., 1983). Infected lymphocytes were then
transplanted into recipient chicken embryos which
had been treated with cyclophosphamide to ablate
their endogenous bursal lymphocyte population.
Histologic examination of the bursas of these
transplanted embryos indicated that the HB1 myc
gene acutely induced formation of pre-neoplastic
follicles. DNAs from these pre-neoplastic follicles
did not induce transformation of NIH 3T3 cells,
indicating that Blym-] was not activated. These
results indicate that myc alone can induce the initial
pre-neoplastic stage of lymphomagenesis and
suggest that activation of Blym-J is associated with
further progression to neoplasia.
In addition to myc and Blym-1 activation in B
cell lymphomas, pairs of transforming genes are
similarly implicated in several other types of
neoplasms. Mouse plasmacytomas involve
activation of myc by chromosomal translocation
(Shen-Ong et al., 1982; Crews et al., 1982) as well
as activation of a distinct transforming gene (tx-2)
detected by transfection (Lane et al., 1982a).
Abelson virus induced mouse pre-B cell lymphomas
involve the viral abl gene as well as a distinct and
unlinked NIH 3T3 transforming gene (tx-1) (Lane
et al., 1982b). Murine leukaemia virus-induced T cell
lymphomas and mouse mammary tumour virus-
induced carcinomas involve activation of genes by
virus integration (MLVI and MM-TVint) (Tsichlis
et al., 1983; Nusse & Varmus, 1982; Peters et al.,
1983) and of unrelated transforming genes detected
by transfection (Tlym-I and tx-4) (Lane et al., 1981,
1984). The activation of two distinct transforming
genes in neoplasms thus appears to be a common
occurrence. By analogy to the myc and Blym-J
combination, these genes may function at distinct
stages of tumour development.
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